Trial reportDiabetes, obesity & metabolism2009
Glycaemic separation and risk factor control in the Veterans Affairs Diabetes Trial: an interim report.
Trial report in Diabetes, obesity & metabolism, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT00032487. Cited by 19 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
CSP #465 - Glycemic Control and Complications in Diabetes Mellitus Type 2 (VADT)
Who cites it
19 citing papers in PubMed, 3 syntheses or guidelines pooled it, 51 citations in OpenAlex.
- Glucose targets for preventing diabetic kidney disease and its progression.The Cochrane database of systematic reviews · 2017Pooled it
- Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials.BMJ (Clinical research ed.) · 2011Pooled it
- Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes.Diabetes care · 2009 · on this mapGuideline
- Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing.Diabetes care · 2009Trial
- Diabetes Mellitus and Heart Failure.Journal of clinical medicine · 2021Review
- Canagliflozin and cardiovascular outcomes in Type 2 diabetes.Future cardiology · 2021Article
- Glycemic Control and Excess Cardiovascular Mortality in Type 1 Diabetes.Current cardiology reports · 2016Review
- Antihyperglycemic and Antiobesity Effects of JAL2 on db/db Mice.Evidence-based complementary and alternative medicine : eCAM · 2016Article
- Prevalence and treatment costs of type 2 diabetes in Germany and the effects of social and demographical differences.The European journal of health economics : HEPAC : health economics in prevention and care · 2015Article
- Current state of diagnosis and management of critical limb ischemia.Current cardiology reports · 2012Review
- Cardiovascular disease in diabetes: where does glucose fit in?The Journal of clinical endocrinology and metabolism · 2011Review
- Evidence linking hypoglycemic events to an increased risk of acute cardiovascular events in patients with type 2 diabetes.Diabetes care · 2011 · on this mapArticle
- Diabetes and Cardiovascular Disease: Is intensive glucose control beneficial or deadly? Lessons from ACCORD, ADVANCE, VADT, UKPDS, PROactive, and NICE-SUGAR.Wiener medizinische Wochenschrift (1946) · 2010Review
- Megatrials in type 2 diabetes. From excitement to frustration?Diabetologia · 2009Review
- Is it possible to reduce cardiovascular risk with glucose-lowering approaches?Nature reviews. Endocrinology · 2009Review
- Potential of glucose-lowering drugs to reduce cardiovascular events.Current diabetes reports · 2009Review
- Vascular effects of rapid-acting insulin analogs in the diabetic patient: a review.Vascular health and risk management · 2009Review
- Article
- Intensive Glycemic Control and Macrovascular Disease in Type 2 Diabetes - A Report on the 44th Annual EASD Meeting, Rome, Italy, September 2008.The review of diabetic studies : RDS · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe Veterans Affairs Diabetes Trial (VADT) will assess the effect of intensive (INT) vs improved standard (STD) glycaemic control on major cardiovascular (CV) events, treating other risk factors equally in both arms. Four-year results of main metabolic parameters are presented. RESEARCH DESIGN AND
methodsVADT is a 7.5 years prospective randomized study of 1791 patients, 20 centres, of men and women of age 60.5 +/- 8.7 years, diagnosed for 11.5 +/- 7.5 years. Their body mass index (BMI) at baseline was 31 +/- 4 kg/m(2) and mean A1C 9.4 +/- 1.5% after maximum dose of oral agents or insulin treatment. Step treatment consists of glimepiride or metformin, rosiglitazone, insulin and other agents; A1C goals are 8-9% in STD and <6% in INT. Lifestyle, blood pressure and lipids are treated uniformly in both arms.
resultsA1C improved in both arms. INT kept median A1C <7% all years, A1C separation is 1.5-1.7%. From year 1 to 4, mean blood pressure is <129/74 mmHg, similar throughout. Median LDL-C was <97 mg/dl by year 1 and triglycerides 150 or less by 2 years. Triglycerides were lower in INT (12-16 mg/dl; p < 0.01). By 4 years, 88% are on lipid-lowering agents and 93% are on antiplatelet/anticoagulant agents. BMI is higher in INT every year (0.9-1.6 kg/m(2); p < 0.01).
conclusionVADT is maintaining the expected A1C in both STD and INT, and LDL-C, triglycerides and blood pressure are at target. The trial is continuing to June 2008. It will be the first long-term completed type 2 diabetes study of the role of glycaemia on CV disease with modern treatments.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.